Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Pluri Inc
PLUR
Healthcare
Biotechnology
Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical...
industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:PLUR)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
Next
(36)
•••
BryceCanada
X
View Profile
View Bullboard History
Post by
BryceCanada
on Mar 26, 2024 6:06pm
Excellent YT analysis on PLUR
https://youtu.be/Cr0Cq1H9JPI?si=AdvJfH3Xp7soFT9x
(76)
•••
lucaM1
X
View Profile
View Bullboard History
Post by
lucaM1
on Jul 27, 2022 8:56am
Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.”
Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company’s Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industries o As of July
...more
Level Up Your Trading with BMO InvestorLine’s Enhanced Features
posted Nov 23, 2024 9:00am by
Bank of Montreal
-
|
Features like Multi-Leg Orders, Options Screener, and Strategy Builder will be particularly exciting for traders. They have been designed to be intuitive and user-friendly, regardless of your experience level. Whether you’re a seasoned pro or just starting out, you’ll find these tools easy to navigate and adapt to your investing style. ...read more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jul 25, 2022 7:00am
New Press Release - Pluri CEO Issues Shareholder Update
HAIFA, Israel, July 25, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”) (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, today issued an update to its shareholders from its Chief Executive Officer and President Yaky...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jul 25, 2022 1:00am
New Press Release - Pluristem Therapeutics Inc. Changes its Name to "Pluri Inc." Reflecting the Company's Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industries
As ofJuly 26, 2022, Pluri’s stock will trade under the symbol PLURThe new name reflects the Company’s strategy to leverage its innovative 3D cell-based technology to a range of fields, developing cell-based products that address various life challenges, while also promoting global wellbeing and...
read article.
(76)
•••
lucaM1
X
View Profile
View Bullboard History
Post by
lucaM1
on Jul 19, 2022 9:51am
Pluristem trial shows accelerated muscle regeneration
Phase III study of allogeneic PLX-PAD cells confirms “regenerative medicine is effective in elderly”. https://longevity.technology/pluristem-trial-shows-accelerated-muscle-regeneration/
(76)
•••
lucaM1
X
View Profile
View Bullboard History
Post by
lucaM1
on Jul 17, 2022 9:52am
HC Wainwright Reiterates On Pluristem After Encouraging Init
Yesterday Pluristem Therapeutics Inc (NASDAQ: PSTI) announced top-line results from its Phase 3 trial evaluating PLX-PAD in 240 patients for muscle recovery following hip fracture
...more
(76)
•••
lucaM1
X
View Profile
View Bullboard History
Post by
lucaM1
on Jul 13, 2022 8:35am
Pluristem's CEO on today's results
“While we were disappointed that this significant benefit did not translate to an SPPB score improvement, Pluristem will seek further regulatory advice to find a way to bridge the gap between
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jul 13, 2022 6:00am
New Press Release - Pluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surgery
The Company will host an analyst and investor call to discuss the phase III muscle regeneration following hip fracture surgery topline results on July 14 at 9:00 a.m. ET; for registration: https://pluristem.zoom.us/webinar/register/WN_kp_CwQQtR-aFtjAXrdiJpAHAIFA, Israel, July 13, 2022 (GLOBE...
read article.
(76)
•••
lucaM1
X
View Profile
View Bullboard History
Post by
lucaM1
on Jul 10, 2022 9:55am
A New Food Ecosystem Emerges in Israel
The story of of Pluristem got into cultured meat. https://www.ift.org/news-and-publications/food-technology-magazine/issues/2022/july/columns/startups-innovators-new-food-ecosystem-israel
(76)
•••
lucaM1
X
View Profile
View Bullboard History
Post by
lucaM1
on Jul 06, 2022 4:06am
Effective Cell Therapy for Cocaine Addiction
Pluristem's Placenta-Derived Mesenchymal-like Adherent Stromal Cells as an Effective Cell Therapy for Cocaine Addiction in a Rat Model https://www.pluristem.com/wp-content/uploads/2022/07
...more
(76)
•••
lucaM1
X
View Profile
View Bullboard History
Post by
lucaM1
on Jul 04, 2022 8:45am
PSTI reminder.
A friendly reminder: If the phase 3 results of the muscle regeneration trials will be positive, the next step would be FDA approval!
(76)
•••
lucaM1
X
View Profile
View Bullboard History
Post by
lucaM1
on Jun 30, 2022 8:57am
$PSTI Q3 Wishlist
1. Results from the multinational Phase III study for muscle regeneration following hip fracture surgery 2. Cultured meat proof of concept.
(76)
•••
lucaM1
X
View Profile
View Bullboard History
Post by
lucaM1
on Jun 13, 2022 8:43am
Cultured meat proof of concept
Cultured meat proof of concept is right around the corner as the company said it will be published in Q2 at their investor call earlier this year.
(76)
•••
lucaM1
X
View Profile
View Bullboard History
Post by
lucaM1
on Jun 07, 2022 9:31am
New PSTI Company blog.
How can Pluristem’s technology help the environment? https://www.pluristem.com/pluristem-blog/how-can-pluristems-technology-help-the-environment/
(76)
•••
lucaM1
X
View Profile
View Bullboard History
Post by
lucaM1
on May 25, 2022 10:22am
Bull run alert!
Bull run alert! Watch out, $PSTI is already up by 6% to start the day!
Prev
1
2
3
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >